NCT07480733 2026-03-25
Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 2 Not yet recruiting
Clinical Trials
9 trialsNCT06840821 2025-12-02
Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors
Mainline Biosciences (Shanghai) Co., Ltd
Phase 1/2 Recruiting
NCT06543056 2025-07-30
A Study of ES014 in Subjects With Advanced Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06888830 2025-06-19
A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Recruiting
NCT04996017 2025-03-13
AtezoMeso
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 3 Recruiting
NCT06208917 2024-01-17
Ondansetron (ODF) Versus Ondansetron Intravenously for the Prevention of Chemotherapy-induced Nausea and Vomiting Compare in Children
Sun Yat-sen University
Phase 3 Recruiting
NCT04601285 2023-07-06
A Phase I Study of JS108 in Patients With Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Terminated
NCT05809336 2023-04-12
Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors
Beijing Friendship Hospital
Phase 2/3 Completed
NCT01163903 2015-07-15
Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours
University Health Network, Toronto
Phase 1 Completed